For adults and children 12+ years with moderate to severe eczema (atopic dermatitis) that did not respond to previous treatment and their eczema is not well controlled using other pills or injections, including biologics, or the use of other pills or injections is not recommended.

RINVOQ helps heal your painful skin in two ways—by significantly reducing the itch and clearing the rash of eczema

Two 16-week clinical trials tested the efficacy and safety of RINVOQ 15 mg and RINVOQ 30 mg in over 200 adolescents (ages 12–17) with moderate to severe eczema (atopic dermatitis).

In these trials, RINVOQ helped provide:

Proven

Skin Clearance

The majority of adolescents taking RINVOQ saw 75% clearer skin, and many saw clear or almost-clear skin at 16 weeks.

Significant

Itch Reduction

Many adolescents taking RINVOQ had significant improvement in itch at 16 weeks.

% of adolescents who achieved

Significantly less itch at 16 weeks

In Study 1, 10% of adolescent patients on placebo, 48% on 15mg of Rinvoq, & 57% on 30mg of Rinvoq. In Study 2, 3% of adolescent patients on placebo, 38% on 15mg of Rinvoq, & 57% on 30mg of Rinvoq.

% of adolescents who achieved

75% skin clearance at 16 weeks

In Study 1, 12% of adolescent patients on placebo, 73% on 15mg of Rinvoq, & 78% on 30mg of Rinvoq. In Study 2, 13% of adolescent patients on placebo, 69% on 15mg of Rinvoq, & 73% on 30mg of Rinvoq.

% of adolescents who achieved

Clear or almost-clear skin at 16 weeks

In Study 1, 7% of adolescent patients on placebo, 45% on 15mg of Rinvoq, & 64% on 30mg of Rinvoq. In Study 2, 5% of adolescent patients on placebo, 45% on 15mg of Rinvoq, & 59% on 30mg of Rinvoq.

The approved starting dose for RINVOQ is 15 mg. In certain cases, your dermatologist may consider increasing to 30 mg. Your dermatologist will prescribe the dose that's right for you. Take RINVOQ exactly as prescribed.

Safety Considerations

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below

"Since starting RINVOQ, I don’t scratch as often…people at school started noticing how my rash was getting better. That was the big moment for me."

—Logan, RINVOQ patient

Picture how

Relief

could look with RINVOQ

It’s time to re-evaluate your treatment expectations. See photos of real people before and after taking RINVOQ.